DESC:
TECHNICAL FIELD
The present disclosure relates to a personal care composition The personal care composition of present disclosure has anti-hair fall, microbial balancing properties, and maintaining good scalp health The personal care composition has good sensorial hair benefits.

BACKGROUND
Hair loss is very common problem in older people. However, as a result of current lifestyle habits and due to hereditary pass on, anyone can experience hair loss problems, including children. According to the American Academy of Dermatology (AAD), there is about a loss of between 50 and 100 hair a day. Generally, new hair replaces the lost hair, but this doesn’t always happen. Hair loss can develop gradually over years or happen abruptly. Hair loss may be temporary or permanent.

Further, premature graying of hair is the second most common problem like hair loss at young age. Common and premature greying (also known as canities) are common and intriguing phenomena frequently discussed in the context of environmental or endogenous processes that lead to an accelerated aging process such as pollution, UV-exposure, inflammation, or even psycho-emotional stress.

In order to prevent the hair fall and premature greying of hair, there are many products available in the market with natural or chemical hair fall agents. Commercially available compositions like cream, hair oil, gel are known to comprises actives like antioxidants, anti-inflammatory, preservatives etc.

Xanthophylls constitute a major part of carotenoids in nature. They are an oxidized version of carotenoid. Xanthophyll has widely drawn scientists' attentions in terms of its functionality, bioavailability and diversity. An assortment of xanthophyll varieties includes lutein, zeaxanthin, ß-cryptoxanthin, capsanthin, astaxanthin, and fucoxanthin. (Ejaz Aziz et. al, Life Sci. 2020 Jan 1;240:117104)
Astaxanthin, a natural strong antioxidant xanthophyll carotenoid, has been demonstrated to contain anti-inflammatory activity. (Siti Nur Hazwani Oslan et. al, Molecules 2021, 26, 6470) Astaxanthin provides cell membranes with potent protection against free radical or other oxidative attack. Experimental studies confirm that this nutrient has a large capacity to neutralize free radical or other oxidant activity in the nonpolar (“hydrophobic”) zones of phospholipid aggregates, as well as along their polar (hydrophilic) boundary zones. (Parris Kidd, Alternative Medicine Review Volume 16, Number 4)

Some prior art compositions are provided below comprising astaxanthin with other components:

CN105746733A relates to novel corn oil prepared from corn oil, corn grains, tea oil, lycopene, astaxanthin, vitamin E, fish bone meal of Harengula zunasi Bleeker and beta-sitosterol. The product has a gold color, good taste and high nutritive value, is easier to absorb for human bodies, can effectively have the efficacy of replenishing calcium, improving the immunity of the human body, resisting oxidation and reducing serum cholesterol, meets demands of vast consumers and is suitable for all people.

4040/KOLNP/2007 relates to a composition includes a lignan, and an additional compound such as an isoflavone, a tocopherol, a phytosterol, a polyphenol, a catechin, an anthocyanin, an astaxanthin, or a glucosamine. The compositions can be formulated as a dietary supplement, in tablet, powder or liquid form, or can be incorporated into a food product.

KR20080022739A relates to self-emulsifying carrier to form nanoparticles voluntarily during the dissolving process, increase the content of lipophilic components, and maintain stability of the active components for a long time, so that it is applied to various applications including cosmetics, medicines and health food. The lipophilic component is astaxanthin, beta-carotene, lycopene, lutein, kaempferol, coenzyme Q10, polyphenol, vitamin E and its derivative, vitamin A and its derivative, provitamin D2 and its derivative, gensenoside, linoleic acid, gamma-linoleic acid, docosahexaenoic acid(DHA), eicosapentaenoic acid(EPA), resveratrol, beta-sitosterol, genistein, oil soluble licorice extract or its mixture.

The importance of folic acid in skeletal muscle cell development was discussed in SEONG YEON HWANG et. al (DOI:10.1002/jcp.25989) This study indicates that folic acid deficiency decreases proliferation and differentiation of C2C12 cells. Though folic acid widely studied for cell proliferation, however it’s topical application and hair-fall benefits has not explored.

Researchers has explored multiple ways to target the hair-fall, however, nowhere the use of Xanthophylls with pharmaceutical actives like folic acid has been studied together. 5 Alpha Reductase considered to be one of the major pathways for providing anti-hair fall benefit. There are no references pertaining to effects of xanthophylls for inhibition of 5 Alpha Reductase present in hair & scalp tissues. According to the inventors of current disclosure, the topical application of Xanthophylls may show 5 Alpha Reductase inhibition and overall higher efficacy while in combination with other actives. Therefore, there was a need to study these actives having multi mechanistic pathways, for further establishing the efficacy.

While conducting the research to provide the benefits of actives, researchers of current invention, unexpectedly found the synergistic activity of xanthophyl derivatives with actives selected either from B-sitosterol or folic acid or arginine or their combination.

Thus, there is a need to provide a personal care composition having enhanced synergism of the ingredients to provide enhanced scalp health and over-all wellbeing of hair.

OBJECTIVES
The main objective of the present disclosure is to provide a personal care composition.

An objective of the present disclosure is to provide a stable composition incorporating actives.

SUMMARY
An aspect of present disclosure provides a personal care composition comprising:
a) 10-9 - 1 wt% of astaxanthin;
b) 10-6 - 1 wt% of a supportive active selected from the group consisting of folic acid, beta-sitosterol and L-arginine or a combination thereof; and
c) q.s. carrier.

These and other features, aspects, and advantages of the present subject matter will become better understood with reference to the following description. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the subject matter, nor is it intended to be used to limit the scope of the subject matter.

BRIEF DESCRIPTION OF DRAWINGS
The above and other features, aspects, and advantages of the subject matter will be better understood with regard to the following description and accompanying drawings where:
Figure 1 shows Concentration vs Cell Viability graph for Folic acid.
Figure 2 shows Concentration vs Cell Viability graph for Astaxanthin.
Figure 3 shows Concentration vs Cell Viability graph for Arginine.
Figure 4 shows Concentration vs Cell Viability graph for Kopexil.
Figure 1 shows Concentration vs Cell Viability graph for Beta-sitosterol.
Figure 6 shows activity of folic acid towards inhibition of 5-alpha reductase enzyme.
Figure 7 shows activity of Astaxanthin towards inhibition of 5-alpha reductase enzyme.
Fig. 8 shows synergistic effect of the combination active, folic acid with astaxanthin.
Fig. 9 shows % Reduction of 5-alpha reductase.
Fig. 10 shows Brdu % cell proliferation.

DETAILED DESCRIPTION
The present disclosure provides a personal care composition comprising: 10-9 - 1 wt% of a xanthophyl, 10-6 - 1 wt% of a supportive active; and q.s. carrier, wherein the supportive active may be selected from the group consisting of folic acid, beta-sitosterol and arginine or a combination thereof. In an embodiment of the present disclosure, the xanthophyll is selected from the group consisting of astaxanthin, lutein, zeaxanthin, neoxanthin, fucoxanthin, violaxanthin, flavoxanthin, capsanthin, cryptoxanthin and a- and ß-cryptoxanthin.

Another embodiment of present disclosure provides a personal care composition comprising 10-9 -1 wt% xanthophyll and 10-6 - 1 wt% folic acid.

Further, an embodiment of present disclosure provides a personal care composition comprising 10-9 - 1 wt% xanthophyll and 10-6 - 1 wt% beta-sitosterol.

Another embodiment of present disclosure provides a personal care composition comprising 10-9 - 1 wt% xanthophyll and 10-6 - 1 wt% L-Arginine

In further embodiment of present disclosure, a personal care composition is disclosed which comprises 10-9 - 1 wt% xanthophyll, 10-6 - 1 wt% folic acid and 10-6 - 1 wt% beta-sitosterol.

Further, an embodiment of present disclosure provides a personal care composition comprising 10-9 - 1 wt% xanthophyll, 10-6 - 1 wt% L-Arginine and 10-6 - 1 wt% beta-sitosterol.

Yet another embodiment of present disclosure provides a personal care composition comprising 10-9 - 1 wt% xanthophyll, 10-6 - 1 wt% L-Arginine and 10-6 - 1 wt% folic acid.

In another embodiment of present disclosure, a personal care composition is disclosed which comprises 10-9 - 1 wt% xanthophyll, 10-6 - 1 wt% folic acid and 10-6 - 1 wt% beta-sitosterol and 10-6 - 1 wt% of L-Arginine.

Yet a preferred embodiment of present disclosure provides that the xanthophyll is astaxanthin.

The present disclosure provides a personal care composition comprising:
a) 10-9 - 1 wt% of astaxanthin;
b) 10-6 - 1 wt% of a supportive active selected from the group consisting of folic acid, beta-sitosterol and L-arginine or a combination thereof; and
c) q.s. carrier.

In an embodiment of the present disclosure, the astaxanthin and the supportive active is present in a ratio in the range of 1:1 to 4:1.

Another embodiment of present disclosure provides that the personal care composition comprises 10-9 - 1 wt% of astaxanthin; and 10-6 - 1 wt% of folic acid.

Yet another embodiment of present disclosure provides that the personal care composition comprises 10-9 - 1 wt% of astaxanthin; and 10-6 - 1 wt% of beta-sitosterol.

Further, an embodiment of present disclosure provides that the personal care composition comprises 10-9 - 1 wt% of astaxanthin; and 10-6 - 1 wt% of L-arginine.

In another embodiment of present disclosure, the personal care composition comprises 10-9 - 1 wt% of astaxanthin; 10-6 - 1 wt% of folic acid; and 10-6 - 1 wt% of beta-sitosterol.

Another embodiment of present disclosure provides that the personal care composition comprises 10-9 - 1 wt% of astaxanthin; 10-6 - 1 wt% of L-Arginine and 0.000001-1 wt% 10-6 - 1 wt% of beta-sitosterol.

In yet another embodiment of the present disclosure, the personal care composition comprises 10-9 - 1 wt% of astaxanthin; 10-6 - 1 wt% of L-Arginine and 0.000001-1 wt% 10-6 - 1 wt% of folic acid.

In another embodiment of present disclosure, the personal care composition comprises 10-9 - 1 wt% of astaxanthin; 10-6 - 1 wt% of folic acid; 10-6 - 1 wt% of beta-sitosterol and 10-6 - 1 wt% of L-Arginine.

Yet another embodiment of present disclosure provides that the carrier is selected from the group consisting of excipients and solvent or a combination thereof.

In another embodiment of the present disclosure, the excipient is selected from the group consisting of one or more emollient, antidandruff agent and antioxidants. Furthermore, the additional excipients may include, but not limited to, plasticizers, polymers, surfactants, binders, preservatives, color, fragrance, emotives, pH regulator, oil, secondary emulsifier, any other active ingredients, pigments, electrolytes (salts), humectants, structurants, conditioners oil and solubilizers or combinations thereof. In preferred embodiment, the excipient is used in the range of 0.000001 to 99.99wt%.

In an embodiment the excipient may be selected from the group consisting of, methyl jasmonate, kopexil, and minoxidil or combination thereof.

In another embodiment of the present disclosure, the antidandruff agents can be selected from the group consisting of Zinc Pyrithione, Piroctone Olamine, Ketoconazole, Tropolone, Hinokitol, Selenium Sulfide, Salicylic Acid, Climbazole, Sodium Salicylate, Ciclopiroxolamine, lchtammol, Sulfur, Clotrimazole, Crotamiton, Zinc Salicylate, Tussilago farfara, Arctium lappa, Zinc Sulfate, Rosmarinus officinalis, Myrtrimonium Bromid, Lactic Acid, Chlorohexidine Digluconate, Phenoxyisopropanol, Isopropanol, Farnesol, Glycolic Acid, Tannic acid, Alcohol, Triclosan, Zinc Gluconate, Zinc PCA, Camphor, Aluminium salts, Sodium Lactate, Polyaminopropyl Biguanide, Zinc Acetate, Triethyl Citrate, Ethylhexylglycerol, Aluminium Circonium, Tetrachlorohydrex GLY, Pentetic Acid, Diisopropylamine Aminoethylpropanol, Zinc Ricinoleate, Aluminium Sesquichlorohydrate, Lactic Acid, imidazole derivatives, glycolic acid, steroids, climbazole and its derivatives. In another embodiment of the present disclosure, the antidandruff agent is salicylic acid.

In another embodiment of the present disclosure, the plasticizer is selected from group consisting of stearic acid, triglycerides; fatty acids, their esters and their alkanolamies, such as glyceryl monostearate, palmitic acid, lauric acid, and myristic or combinations thereof.

In another embodiment of the present disclosure, the polymers are selected from the group consisting of silicone polymers; water soluble polymers such as polyurethanes, polyacrylates, polyalkylene glycol with molecular weight between 200 and 20,000, preferably between 400 and 10,000 such as PEG 200, PEG 400, PEG600, PEG 1500, PEG 4000, PEG 6000, PEG 8000 and the like; anionic, zwitterionic, amphoteric and nonionic polymers that can be used are, for example, vinylacetate/crotonic acid-copolymers, vinylpyrrolidone/vinylacrylate copolymers, vinylacetate/butylmaleate/ isobornylacrylate-copolymers, methylvinylether /maleic acid anhydride-copolymers and their esters, which are not cross-linked and with polyols linked polyacrylacids which are cross-linked, acryl amidopropyltrimethylammonium chloride/ acrylate-copolymers, octylacrylamide/methylmethacrylate/tert.butylaminoethylmethacrylate/2-hydroxypropylmethacrylate- 25 copolymers, polyvinylpyrrolidone, vinylpyrrolidone/vinylacetate-copolymers, vinylpyrrolidone/ dimethylaminoethylmethacrylate/vinyl caprolactam-terpolymers as well as optionally derivatized cellulose ethers and silicones.

In another embodiment of the present disclosure, the personal care composition further comprises surfactants which are selected from the group consisting of anionic surfactants, nonionic surfactants, sugar-based surfactants and amphoteric surfactants.

In another embodiment of the present disclosure, the anionic surfactants that may be used in the present invention include but are not limited to acyl isethionates, sodium cocoyl isethionate, sodium isethionate, sodium lauroyl isethionate, sodium lauroyl methyl isethionate, sodium methyl cocoyl taurate, and the series, sodium alkyl sulfate, alkyl sulfates, anionic acyl sarcosinates, methyl acyl taurates, N-acyl glutamates, acyl isethionates, alkyl ether sulfates, alkyl sulfosuccinates, alkyl phosphate esters, ethoxylated alkyl phosphate esters, trideceth sulfates, protein condensates, mixtures of ethoxylated alkyl sulfates sodium cocoyl Apple amino acids surfactants, sodium lauryl sarcosinate and the like. Alkyl chains for these surfactants are C8-22, preferably C10-18 and, more preferably, C12-14 alkyls.

The nonionic surfactants useful in this present disclosure can be defined as compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound, which may be aliphatic or alkyl aromatic in nature. Non-limiting examples of preferred nonionic surfactants for use herein are those selected form the group consisting of PEG-8-Caprylic Capric triglycerides, Polysorbate 20, sorbitan monolaurate, Polyethylene glycol propylene glycol cocoates, PEG-40 Hydrogenated Castor Oil, glucose amides, decyl glucoside, alkyl glucoside, alkyl polyglucosides, sucrose cocoate, sucrose laurate, alkanolamides, ethoxylated alcohols, PEG modified triglycerides, PEG -40 Sorbitan Perisostearate, PEG 40 Stearate, PEG 80 Glyceryl Cocoate, PEG 120 Methyl Glucose Dioleate, PEG 150 Distearate, PEG 200 Hydrogenated Glyceryl Palmate, PEG 7 Glyceryl Cocoate, Polysorbate 40, Polysorbate 60, Polysorbate 80 and mixtures thereof. In a preferred embodiment the nonionic surfactant is selected from the group consisting of glyceryl monohydroxystearate, isosteareth-2, trideceth-3, hydroxystearic acid, propylene glycol stearate, PEG-2 stearate, sorbitan monostearate, glyceryl laurate, laureth-2, cocamide 30 monoethanolamine, lauramide monoethanolamine, decyl glucoside and mixtures thereof.

The composition of the present disclosure may also comprise one or more sugar based surfactants selected from but not limited to condensation products of long chain alcohols with sugar or starch polymers (e.g. decyl polyglucoside and lauryl polyglucoside), amides (e.g. cocoamide diethanolamine and cocoamide monoethanolamine), alkylene oxide derived surfactants (e.g. ceteth-6, ceteareth6, 5 steareth-6, PEG-12 stearate, and PEG-200 glyceryl tallowate), Maltooligosyl Glucoside/Hydrogenated Starch Hydrolysate and mixtures thereof.

The composition of the present disclosure can optionally comprise of amphoteric surfactants. The amphoteric surfactants which can be used in the compositions of the present invention are those which can be broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight chain or branched and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate. Examples of compounds falling within this definition are CDMA, sodium 3-dodecylaminopropionate, sodium 3- 15 dodecylaminopropane sulfonate. Other amphoterics such as betaines are also useful in the present composition. Examples of betaines useful herein include the high alkyl betaines such as coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxy-methyl betaine, lauryl dimethyl alpha-carboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, lauryl bis-(2-hydroxyethyl)carboxy methyl betaine, stearyl bis-(2- 20 hydroxypropyl)carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl bis-(2-hydro-xypropyl)alpha-carboxyethyl betaine, etc. The sulfobetaines may be represented by coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, amido betaines, amidosulfobetaines, and the like. The composition of the present disclosure can optionally comprise of cationic surfactants. Cationic surfactants that may be added to the current invention include but are not limited to aliphatic amine or its quaternary ammonium salts, fatty acid amine salt, acylcarboxylic Phenylguanidine derivatives, mono-N-long chain lower alkyl amino acid or basic amino antitackiness, benzalkonium salt alkyl, oxoimidazolinium salt or the like are used.

In another embodiment of the present disclosure, the binders include high molecular weight polyethylene glycols (PEGs) like PEG 6000, PEG 8000, poly acrylates, high molecular weight poly-ox, silicates, fatty alcohols, lanolin, sugars, tallow alcohol ethoxylates, and mixtures thereof.

In another embodiment of the present disclosure, the preservatives are used in the range of 0.0001 to 2 wt% and the preservatives may be selected from the group consisting of BHT, EDTA, phenoxy ethanol and hydantoin.

In another embodiment of the present disclosure, pH regulator is used in the range of 0.0001 to 2% and the pH regulator includes citric acid, lactic acid, oxalic acid, acetic acid, triethanolamine, sulphuric acid etc.

In another embodiment of the present disclosure, the structurants are selected from the group consisting of polymers.

In another embodiment of the present disclosure, the conditioners are selected from the group consisting of silicones, and polyquats or combinations thereof. In a preferred embodiment of the invention, the conditioner is silicones and present in amount of ¬¬¬¬0.01 to 99wt. % in the final product.

In another embodiment of the present disclsoure, the solubilizers can be chosen from, PEG/PPG 18/18 dimethicone, PEG-3 dimethicone, PEG 12 dimethicone, PEG 10 dimethicone, PEG 60/35/40/n hydrogenated castor oil, oleth-5, C12-15 Alkyl Benzoate, Dibutyl Adipate, Dicaprylyl Carbonate, Propylheptyl Caprylate, Capramide DEA, Potassium Caprylate, Potassium Caprylate/caprate, Arlatone 975, Oleth-2, PEG 75 lanolin, Octoxynol-11, Lauryl PEG-9 Polydimethylsiloxyethyl 8 dimethicone, Isoceteth-20 and PEG-7 Olivate.

In another embodiment of the present disclosure, the personal care composition of present disclosure may comprise phospholipids. Suitable phospholipids may include phosphatidylcholine (lecithin) (PC), phosphatidyl 20 ethanolamine (PE), phosphatidyl serine (PS), lyso phospholipids, Phosphatidic acid (phosphatidate) (PA), phosphoinositides such as Phosphatidylinositol (PI), phosphatidylinositol phosphate (PIP), phosphatidylinositol bisphosphate (PIP2), phosphatidylinositol triphosphate (PIP3), phosphosphingolipids such as ceramidephosphorylcholine (Sphingomyelin) (SPH), ceramidephosphorylethanolamine 25 (Sphingomyelin) (Cer-PE), ceramidephosphoryllipid, natural phospholipids such as egg PC, egg PG, soy PC, hydrogenated soy PC, sphingomyelin, lecithin separated from soya lecithin, egg lecithin, rice bran lecithin, combinations and derivatives thereof. In the preferred embodiment of the invention, the phospholipid is phosphatidylcholine (lecithin) (PC).

In another embodiment of the present disclosure, the solvent may be organic or inorganic or combination thereof.

In yet another embodiment of the present disclosure, the solvents may include water. In yet another embodiment of the invention, the solvents may be purified water.

In another embodiment of the present disclosure, the solvents may be hydrophilic or hydrophobic in nature.

In another preferred embodiment of the present disclosure, the solvents may include polyhydric alcohols such as but not limited to ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, polyethylene glycol, sorbitol, glycerine, xylitol, mannitol, their derivatives and mixture thereof.

Folic acid also known as vitamin B9 or Folate have stability at alkaline pH. Arginine also known as L-Arginine, an alpha amino acid on other hand act as basic amino acid at neutral pH. The researchers formed a Folic acid, L-Arginine complex while developing the formulation. The water-based formulation developed according to one of the embodiment comprising folic acid L-Arginine complex.

In another embodiment of the present disclosure, said personal care composition may be transparent, suspending, translucent or opaque in nature.

In another embodiment of the present disclosure, there is provided that the composition can be formulated as oil, crème, biphasic, gel, solutions, suspensions, dispersions, emulsions, microformulations, nano formulations, nano carriers, lipid based systems, colloidal dispersions, polymer based systems, creams, lotions likewise.

In another embodiment of the present disclosure, the personal care composition is a topical composition.

Further an embodiment of present disclosure provides that the personal care composition has anti-hair fall benefits. The same has been studied on cell-line.

The composition of the present disclosure can be formulated into various topical product forms such as shampoo, conditioners, hair spray/mist, hair-mask, hair cremes, hair serums, hair gels, anti-ageing formulations, skin cremes, moisturizers and other types.

EXAMPLES
The following examples are given by way of illustration of the present invention and should not be construed to limit the scope of present disclosure. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are intended to provide further explanation of the subject matter.

Example 1: A personal care composition is prepared by a) heating astaxanthin, with a solvent followed by stirring to obtain an astaxanthin mixture; b) heating supportive actives, with a solvent followed by stirring to obtain an active mixture; c) mixing the astaxanthin mixture and active mixture to obtain an astaxanthin-supportive active mixture; and d) adding an excipient under stirring and mixing to obtain the personal care composition. The prepared composition has following ingredients in given wt% content:

Ingredients % (w/w)
Propylene Glycol 3
Polysobate 80 1.4
Methyl Paraben 0.3
Folic Acid 0.001
Arginine 0.001
Acrylates/C10-30 Alkyl Acrylate Crosspolymer 0.22
Isopropyl myristate 17
Astaxanthin 0.00001
b – sitosterol 0.001
Sorbitan Oleate 1.6
Propyl Paraben 0.1
Glyceryl Stearate 1
Cetyl alcohol 1.5
Butylated hydroxytoluene 0.05
Amodimethicone/Morpholinomethyl Silsesquioxane (and) Trideceth-5 (and) Glycerin 3
Triethyl amine 0.18
Phenoxyethanol 0.25
Perfume 0.5
Water Q.S. to 100
Table 1
Example 2: A personal care composition is prepared having ingredients as a tonic formulation (Astaxanthin + Folic acid in ratio 1:1)
Table 2: At low concentration of Folic acid and astaxanthin

Sr. No. Ingredient % (w/w)
1 Hydroxyethylcellulose 0.5
2 Propylene Glycol 5
3 Phenoxyethanol 0.3
4 Disodium EDTA 0.1
5 Folic Acid 0.001
6 Polyethylene Glycol 400 2
7 Polysobate 80 1
8 Astaxanthin 0.001
9 PEG-40 Hydrogenated Castor Oil 5
10 Perfume 2
11 Ethanol 20
12 Water Q.S. to 100

Table 3: At high concentration of Folic acid and Astaxanthin
Sr. No. Ingredient % (w/w)
1 hydroxyethylcellulose 0.5
2 Propylene Glycol 5
3 Phenoxyethanol 0.3
4 Disodium EDTA 0.1
5 Folic Acid 1
6 Polyethylene Glycol 400 2
7 Polysobate 80 1
8 Astaxanthin 1
9 PEG-40 Hydrogenated Castor Oil 5
10 Perfume 2
11 Ethanol 20
12 Water Q.S to 100

Example 3: A personal care composition is prepared having ingredients as a tonic formulation (Astaxanthin + Folic acid in ratio 4:1)
Table 4:
Sr. No. Ingredient % (w/w)
1 hydroxyethylcellulose 0.5
2 Propylene Glycol 5
3 Phenoxyethanol 0.3
4 Disodium EDTA 0.1
5 Folic Acid 0.2
6 Polyethylene Glycol 400 2
7 Polysobate 80 1
8 Astaxanthin 0.8
9 PEG-40 Hydrogenated Castor Oil 5
10 Perfume 2
11 Ethanol 20
12 Water Q.S to 100

Example 4: A personal care composition is prepared having ingredients as a hair/skin oil formulation (Astaxanthin + beta-sitosterol in ratio 1:1)
Table 5: At low concentration of astaxanthin and beta-sitosterol
Sr. No. Ingredients % (w/w) 1:1
1 Astaxanthin 0.001
2 b - sitosterol 0.001
3 tert-Butylhydroquinone 0.2
4 Perfume 0.5
5 Color 0.001
6 Mineral Oil Q.S. to 100

Table 6: At high concentration of astaxanthin and beta-sitosterol
Sr. No. Ingredients % (w/w)
1 Astaxanthin 1
2 b - sitosterol 1
3 tert-Butylhydroquinone 0.2
4 Perfume 0.5
5 Color 0.001
6 Mineral Oil Q.S. to 100

Example 5: A personal care composition is prepared having ingredients as a hair/skin oil formulation (Astaxanthin + beta-sitosterol in ratio 3:1)
Table 7:
Astaxantin to b - sitosterol ratio 3:1
Sr. No. Ingredients % (w/w)
1 Astaxanthin 0.3
2 b - sitosterol 0.1
3 tert-Butylhydroquinone 0.2
4 Perfume 0.5
5 Color 0.001
6 Mineral Oil Q.S. to 100

Example 6: A personal care composition is prepared having ingredients as a hair/skin oil formulation (Astaxanthin + beta-sitosterol in ratio 2:1)
Table 8:
Astaxantin to b - sitosterol ratio 2:1
Sr. No. Ingredients % (w/w)
1 Astaxanthin 0.2
2 b - sitosterol 0.1
3 tert-Butylhydroquinone 0.2
4 Perfume 0.5
5 Color 0.001
6 Mineral Oil Q.S. to 100

Example 7 (a): Comparative formulation (Astaxanthin + beta-sitosterol outside the concentration range)
Table 9: Low concentration out side
Sr. No. Ingredients % (w/w)
1 Astaxanthin 0.00000001
2 b - sitosterol 0.00000001
3 tert-Butylhydroquinone 0.2
4 Perfume 0.5
5 Color 0.001
6 Mineral Oil Q.S. to 100

Example 7 (b): Comparative formulation (Astaxanthin + beta-sitosterol outside the concentration range)
Table 10: High Concentration outside
Sr. No. Ingredients % (w/w)
1 Astaxanthin 1.5
2 b - sitosterol 1.5
3 tert-Butylhydroquinone 0.2
4 Perfume 0.5
5 Color 0.001
6 Mineral Oil Q.S. to 100

Example 8: A personal care composition is prepared having ingredients as biphasic oil formulation (Folic acid+Astaxanthin+Arginine+betasitasterol )
Table 11: Low concentration
Sr. No. Phase Ingredients % (w/w)
1 Water Folic Acid 0.001
2 Arginine 0.001
3 Glycerine 20.0
4 Water 20.0
5 Oil Astaxanthin 0.001
6 b - sitosterol 0.001
7 tert-Butylhydroquinone 0.2
8 Perfume 0.5
9 Mineral Oil Q.S. to 100

Table 12: High concentration
Sr. No. Phase Ingredients % (w/w)
1 Water Folic Acid 1.0
2 Arginine 1.0
3 Glycerine 20.0
4 Water 20.0
5 Oil Astaxanthin 1.0
6 b - sitosterol 1.0
7 tert-Butylhydroquinone 0.2
8 Perfume 0.5
9 Mineral Oil Q.S. to 100

Table 13:
Astaxanthin:Folic acid:Arginine:b-sitosteril Ratio 4:2:1:1
Sr. No. Phase Ingredients % (w/w)
1 Water Folic Acid 0.2
2 Arginine 0.1
3 Glycerine 20.0
4 Water 20.0
5 Oil Astaxanthin 0.4
6 b - sitosterol 0.1
7 tert-Butylhydroquinone 0.2
8 Perfume 0.5
9 Mineral Oil Q.S. to 100

Example 9: A personal care composition is prepared having ingredients as crème formulation (Folic acid+Astaxanthin+Arginine+betasitasterol)
Table 14:
Sr.No. Ingredients % (w/w)
1 Propylene Glycol 3
2 Polysobate 80 1.4
3 Methyl Paraben 0.3
4 Folic Acid 0.001
5 Arginine 0.001
6 Acrylates/C10-30 Alkyl Acrylate Crosspolymer 0.22
7 Isopropyl myristate 20
8 Astaxanthin 0.001
9 b - sitosterol 0.001
10 Sorbitan Oleate 2
11 Propyl Paraben 0.1
12 Glyceryl Stearate 1
13 Cetyl alcohol 1.5
14 Butylated hydroxytoluene 0.05
15 Amodimethicone/Morpholinomethyl Silsesquioxane (and) Trideceth-5 (and) Glycerin 3
16 Triethyl amine 0.18
17 Phenoxyethanol 0.25
18 Perfume 1
19 Water Q.S. to 100

Table 15: At different ratio (4:1)
Sr.No. Ingredients % (w/w)
1 Propylene Glycol 3
2 Polysorbate 80 1.4
3 Methyl Paraben 0.3
4 Folic Acid 0.2
5 Arginine 0.2
6 Acrylates/C10-30 Alkyl Acrylate Crosspolymer 0.22
7 Isopropyl myristate 20
8 Astaxanthin 0.8
9 b - sitosterol 0.2
10 Sorbitan Oleate 2
11 Propyl Paraben 0.1
12 Glyceryl Stearate 1
13 Cetyl alcohol 1.5
14 Butylated hydroxytoluene 0.05
15 Amodimethicone/Morpholinomethyl Silsesquioxane (and) Trideceth-5 (and) Glycerin 3
16 Triethyl amine 0.18
17 Phenoxyethanol 0.25
18 Perfume 1
19 Water Q.S. to 100

Example 10: A personal care composition is prepared having ingredients as tonic formulation (Folic acid+Astaxanthin+Arginine+betasitasterol)
Table 16:
Sr. No. Ingredient % (w/w)
1 hydroxyethylcellulose 0.5
2 Propylene Glycol 5
3 Phenoxyethanol 0.3
4 Disodium EDTA 0.1
5 Folic Acid 0.002
6 Arginine 0.002
7 Polyethylene Glycol 400
8 Polysobate 80
9 Astaxanthin 0.002
10 b – sitosterol 0.002
12 PEG-40 Hydrogenated Castor Oil 5
13 Perfume 0.5
14 Ethanol 20
16 Water Q.S. to 100

Example 11: Test methods & Protocols
MTT assay
The Highest Non-Cytotoxic concentration (NCC) was calculated basis the % Cell viability obtained for the concentrations tested. Cells were seeded in Duplicates. The highest concentration having viability > 100% was the Highest non-cytotoxic Concentration.

A. MATERIALS & EQUIPMENTS:
(Thermo) CyQUANT™ MTT Cell Proliferation Assay Kit (V13154), ELISA Reader (Cytation 3 Biotek), Micro Pipettes, sterile 96 well plate, unused tips & eppendorf tubes, Discard bin, Incubator
Software: Gen 5.0

B. PROCEDURE:
B.1 Preparation of MTT Stock solution:
To prepare 12-mM MTT stock solution, add 1 mL of sterile PBS to one 5-mg vial of MTT. Vortex to mix or sonicate the solution until it is dissolved. MTT stock solution can be stored at 4°C for up to 4 weeks when protected from light using aluminum foil.
B.2 Assay Protocol:
• Seed the 96 well plate with desired no of wells with 104 cells /well and incubate at 37°C for 24hrs. Allow cell to attach to surface.
• After 24hrs, replace the media with appropriate concentration of drug/ actives to be tested.
• For adherent cells, remove the medium, then add 100 µL of fresh culture medium containing actives for 24hrs.
• For non-adherent/suspension cells, centrifuge the plate at 1000 rpm for 5 min, carefully remove as much medium as possible from the well, then resuspend the cells in 100 µL of fresh medium containing actives.
• Add 100 µL of the MTT working solution to each well by replacing the old media with actives.
• Incubate at 37°C for 4 hours.
• After 4 hrs of incubation, remove all but keep 25 µL of MTT working solution and add 50 µL of DMSO in each well, Mix well and avoid bubble forming in plate.
• Incubate at 37°C for 10 min.
• Pipette up and down to mix each sample again, then read the absorbance at 570 nm, Using Cytation 3 plate reader, and Gen 5 Software.
• Check the plate under the microscope for Complete dissolution of MTT formazan crystals.

Cell Proliferation by BrdU Assay
The highest non-cytotoxic concentration was tested for cell-proliferation of dermal papilla cells. % of cells proliferated were calculated basis comparison with untreated cells post 24 hours incubation with test substance at the highest NCC. Insulin is taken as a positive control and SDS (Sodium Dodecyl Sulfate) is used as a negative control. Cells were seeded in Duplicates.

1. MATERIALS & EQUIPMENTS: Brdu ELISA kit, ELISA Reader (Cytation 3 Biotek), Micro Pipettes, 96 well plate, Eppendorf tube, Discard Bin and Shaker, Micropipette Tips (1mL, 200µL, 100 µL)

2. PROCEDURE
• Seed 1 x 104 cells per well in a 96 well plate with the respective media for that particular cell line and allow them to grow for approximately 24hrs for attachment in the incubator at 37°C & 5% CO2. Post 24hrs, replace the media with fresh complete media containing fixed concentrations of test substances/actives/extract, to a final volume of 100 µL/ well. Incubate the plate in a humidified atmosphere at 37°C and 5% CO2 for next 24h.
• To check the cell proliferation, prepare BrdU labelling solution from stock, Brdu labelling solution stock: media (1:100). Add 100µL of this to each well and incubate at 37°C and 5% CO2 for next 4h.
• Remove labeling medium from adherent cells by tapping off or pipetting out using 200µL pipette. – For suspension cells, centrifuge the microplate at 1000 rpm for 5 minutes in the centrifuge, then flick off or aspirate by pipetting.
• Add 200 µL/well FixDenat (Bottle 2) to the cells using the 200µL pipette. – Incubate for 30 minutes at +15 to 25°C (RT).
• Remove FixDenat solution thoroughly by flicking off and tapping.??
• Prepare Anti-BrdU-POD working solution: Anti-Brdu-POD stock solution: Antibody dilution solution (1:100) Add 100 µL/well of Anti-BrdU-POD working solution using the 100µL pipette and tips – Incubate for approximately 90 minutes at 15 to 25°C (RT).
• Remove Anti-Brdu-POD working solution by flicking off and rinse wells three times with 200 µL/well using the multichannel pipette and the 200µL pipette.1X washing buffer (Prepare this from provided 10 X washing buffer).??
• Remove the washing solution by tapping or aspirate using pipette.
• Add 100 µL/well Substrate Solution. – Incubate at +15 to +25°C (RT) until color development is sufficient for photometric detection for 20mins.
• Add 25 µl 1M H2SO4 (stop solution) to each well mix thoroughly by pipetting. – Measure the absorbance of the samples in an ELISA reader at 450 nm with 30s of shaking in the software protocol.
• Compare the cell proliferation using OD values of test with untreated sample.

5-Alpha Reductase inhibition Assay
1. Definition
This ELISA assay works on the Sandwich ELISA principle. The 96-well plate is pre-coated with capture antibody. Different concentrations of standards and unknown samples containing the antigen(5-a-reductase) is added to the plate. Detection antibody conjugated to Biotin is added which binds to the antigen. An HRP is then added which binds to the biotin. The TMB substrate added reacts with the HRP and develops colour. Sulfuric acid (Stop solution) added to the wells terminates the colour development reaction and the absorbance is measured at 450nm. The concentration of the unknown sample can be calculated by comparing its OD value with known OD values obtained on the standard curve to determine the concentration of the antigen (5-a reductase).
2. Materials
PC3- prostate cancer Cell line, Human 5-alpha reductase / SRD5A2 ELISA Kit (Sandwich ELISA) by LSBio Inc. (USA)
3. Procedure
The assay was performed using manufacturer’s instructions for quantification of 5-a-reductase. The OD was measured at 450nm using the Cytation 3 microplate reader and analysed with Gen 5.0 software.

Example 12: MTT cell viability data
Cell viability for each component is detected through MTT assay as explained above. Figs. 1-5 show Cell viability graphs for individual components of the composition.
1. Folic Acid (Fig. 1)-

Concentration of Folic acid (%) Cell Viability (%)
0.000000001% (10^-9) 124.2%
0.00000001% (10^-8) 121.6%
0.0000001% (10^-7) 120.4%
0.000001% (10^-6) 113.3%
0.00001% (10^-5) 118.7%
0.0001% (10^-4) 111.5%
0.001% (10^-3) 98.4%
0.01% (10^-2) 90.00%
0.1% (10^-1) 88.30%
1% 55.40%

2. Astaxanthin (Fig. 2) -
Concentration of Astaxanthain (%) Cell Viability (%)
0.000000001% (10^-9) 119.8%
0.00000001% (10^-8) 119.3%
0.0000001%(10^-7) 113.9%
0.000001% (10^-6) 109.0%
0.00001% (10^-5) 107.5%
0.0001% (10^-4) 104.9%
0.001% (10^-3) 94.2%
0.01% (10^-2) 87.10%
0.1% (10^-1) 83.30%
1% 75.60%

3. Arginine (Fig. 3) -
Concentration of Arginine (%) Cell Viability (%)
0.00000001% (10^-8) 134.70%
0.0000001%(10^-7) 132.57%
0.000001% (10^-6) 113.91%
0.00001% (10^-5) 101.15%
0.0001% (10^-4) 95.32%
0.001% (10^-3) 90.83%
0.01% (10^-2) 81.51%
0.1% (10^-1) 81.83%
1% 79.23%

4. Kopexil (Fig. 4) -
Concentration of Kopexil (%) Cell Viability (%)
0.00000001% (10^-8) 115.9%
0.0000001%(10^-7) 110.4%
0.000001% (10^-6) 104.3%
0.00001% (10^-5) 101.3%
0.0001% (10^-4) 96.4%
0.001% (10^-3) 92.5%
0.01% (10^-2) 83.0%
0.1% (10^-1) 71.4%
1% 59.9%

5. Beta-sitosterol (Fig. 5) -
Concentration of Beta- Sitosterol (%) Cell Viability (%)
0.00000001% (10^-8) 111.79%
0.0000001%(10^-7) 109.33%
0.000001% (10^-6) 105.85%
0.00001% (10^-5) 100.21%
0.0001% (10^-4) 92.31%
0.001% (10^-3) 85.11%
0.01% (10^-2) 84.78%
0.1% (10^-1) 78.23%
1% 70.05%

The highest non-cytotoxic concentration chosen for synergy assays.

Example 13: % inhibition of 5-alpha reductase enzyme by Folic Acid and Asatxanthin.
% inhibition of 5-alpha reductase enzyme was calculated on the entire concentration range Folic Acid and Astaxanthin. Fig. 6-7 shows individual activities of folic acid and astaxanthin respectively, towards inhibition of 5-alpha reductase enzyme. The results obtained are given in Table 17 and Table 18 below:
Table 17. Folic Acid - Individual Activity
Table 17. Folic Acid - Individual Activity Concentration in ug/ml % inhibition of 5-Alpha Reductase Enzyme
0.000000001 (10^-9) 0.00001 0.5%
0.00000001 (10^-8) 0.0001 2.1%
0.0000001(10^-7) 0.001 7.0%
0.000001 (10^-6) 0.01 7.3%
0.00001 (10^-5) 0.1 10.8%
0.0001 (10^-4) 1 13.1%
0.001 (10^-3) 10 7.0%

Table 18. Astaxanthin - Individual Activity
Concentration in Percentage Concentration in ug/ml % inhibition of 5-Alpha Reductase Enzyme
0.000000001 (10^-9) 0.00001 25.5%
0.00000001 (10^-8) 0.0001 35.3%
0.0000001(10^-7) 0.001 21.0%
0.000001 (10^-6) 0.01 20.0%
0.00001 (10^-5) 0.1 16.6%
0.0001 (10^-4) 1 19.8%
0.001 (10^-3) 10 15.2%

Further, the synergistic effect of the combination of active, folic acid with astaxanthin is evaluated (Fig. 8) and the results are given in Table 19 below:
Table 19. Synergy Data for Ratios of Astaxanthin and Folic acid
Concentration of Astaxanthin (ug/ml) Concentration of Folic Acid (ug/ml) Ratio of Astaxanthin: Folic Acid % inhibition of 5-Alpha Reductase Enzyme
0.000080 0.20 4:1 48%
0.000075 0.25 3:1 65%
0.000067 0.33 2:1 76%
0.000050 0.50 1:1 98%
0.000033 0.67 1:2 16%
0.000025 0.75 1:3 21%
0.000020 0.80 1:4 26%

Example 14: % Reduction of 5-alpha reductase (Fig. 9) and Brdu % cell proliferation (Fig. 10).
Table 20
Sample ID % Reduction of 5-AR
Positive Control- Finasteride 100.00%
Negative Control- Testosterone 0.00%
Astaxanthin (10^-8%) 35.31%
Folic Acid (10^-4%) 13.12%
Arginine ( 10^-5%) 20.53%
Kopexil (10^-7%) 15.82%
Beta-Sitosterol (10^-7%) 18.20%
Astaxanthin+ folic Acid (1:1) 98.34%
Arginin+ Folic Acid (1:1) 68.10%
Astaxanthin+ B sitosterol (1:1) 92.04%
Astaxanthin + B sitosterol+ Folic acid (1:1:1) 86.47%
Astaxanthin + B sitosterol+ Folic acid+Arginin (1:1:1:1) 84.92%
Astaxanthin + B sitosterol+ Folic acid +Arginin+Kopexil (1:1:1:1:1) 90.59%

Table 21:

Sample ID Brdu % cell proliferation
Positive Control- Insulin 130.0
Negative Control- SDS 12.4
Astaxanthin (10^-8%) 144.9
Folic Acid (10^-4%) 142.5
Arginine ( 10^-5%) 126.5
Kopexil (10^-7%) 118.1
Beta-Sitosterol (10^-7%) 116.5
Astaxanthin+ folic Acid (1:1) 156.2
Arginin+ Folic Acid (1:1) 146.9
Astaxanthin+ Beta- sitosterol (1:1) 130.9
Astaxanthin + Beta- sitosterol + Folic acid (1:1:1) 153.9
Astaxanthin + Beta- sitosterol + Folic acid+Arginin (1:1:1:1) 151.4
Astaxanthin + Beta- sitosterol + Folic acid +Arginin+Kopexil (1:1:1:1:1) 151.0

Example 15: Sensory Test: To evaluate the efficacy of the test products in improving overall hair and scalp health.
Study Duration: Approximately 8 weeks for each subject
Subject‘s gender and age range: Male and female subjects aged between 18-45 years (both ages inclusive).
Sample Size: 15 subjects for one product

Questions are related to hair fall rate, effectiveness of product, grading of hair fall, overall effectiveness etc. Samples used for the sensory test on the subject is provide below:

Sample Formulation Conc w/w %
1 Negative Control 0
2 Asta+folic acid 1+1
3 Asta+folic acid (Outside Rnge)) 1.5+1.5
4 Astaxanthin+ B sitosterol (1:1) 1+1
5 Astaxanthin+ B sitosterol (1:1) (Outside Range) 1.5+1.5
6 Astaxanthin + B sitosterol+ Folic acid (1:1:1) 1+1+1
7 Astaxanthin + B sitosterol+ Folic acid+Arginin (1:1:1:1) 1+1+1+1
8 Astaxanthin + B sitosterol+ Folic acid +Arginin+Kopexil (1:1:1:1:1) 1+1+1+1+1

Outside Outside
Ratio 01:01 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8
Sr. No. Phase Ingredients % (w/w) % (w/w) % (w/w) % (w/w) % (w/w) % (w/w) % (w/w) % (w/w)
1 Water Folic Acid 0.00 1.00 1.50 0.00 0.00 1.00 1.00 1.00
2 Arginine 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00
3 Glycerine 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
4 Kopexil 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
5 Water 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00
6 Oil Astaxanthin 0.00 1.00 1.50 1.00 1.50 1.00 1.00 1.00
7 b - sitosterol 0.00 0.00 0.00 1.00 1.50 1.00 1.00 1.00
8 tert-Butylhydroquinone 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
9 Perfume 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50
10 Mineral Oil Q.S. to 100 Q.S. to 100 Q.S. to 100 Q.S. to 100 Q.S. to 100 Q.S. to 100 Q.S. to 100 Q.S. to 100

Sample 9 (Astaxanthin only) Sample 10 (Folic acid only) Sample 11 (betasitosterol only)
% (w/w) % (w/w) % (w/w)
0.00 1.00 0.00
0.00 0.00 0.00
20.00 20.00 20.00
0.00 0.00 0.00
20.00 20.00 20.00
1.00 0.00 0.00
0.00 0.00 1.00
0.20 0.20 0.20
0.50 0.50 0.50
Q.S. to 100 Q.S. to 100 Q.S. to 100

? Consumer Rating Average in terms of overall effectiveness of the product on the scalp & hair problem (1 - poor; 10 - excellent)
Formulation Consumer Rating Avg
Sample 1 2.4
Sample 2 8.8
Sample 3 6
Sample 4 8
Sample 5 6.2
Sample 6 9.2
Sample 7 8.2
Sample 8 8.4
Sample 9 3.6
Sample 10 2.8
Sample 11 2.6

Although the subject matter has been described in considerable detail with reference to certain preferred embodiments thereof, other embodiments are possible. As such, the spirit and scope of the subject matter should not be limited to the description of the preferred embodiment contained therein. ,CLAIMS:WE CLAIM:
1. A personal care composition comprising:
a) 10-9 - 1 wt% of astaxanthin;
b) 10-6 - 1 wt% of a supportive active selected from the group consisting of folic acid, beta-sitosterol and L-arginine or a combination thereof; and
c) q.s. carrier.

2. The personal care composition as claimed in claim 1, wherein the astaxanthin and the supportive active is present in a ratio in the range of 1:1 to 4:1.

3. The personal care composition as claimed in claim 1, wherein the carrier selected from the group consisting of excipients and solvent or a combination thereof.

4. The personal care composition as claimed in claim 3, wherein the excipients are selected from the group consisting of oil, emollient, antidandruff agent, antioxidants, plasticizers, polymers, surfactants, binders, preservatives, color, fragrance, emotives, pH regulator, water, secondary emulsifier, active ingredients, pigments, electrolytes (salts), humectants, structurants, conditioners, and solubilizers or combinations thereof.

5. The personal care composition as claimed in claim 3, wherein the excipients are selected from the group consisting of selected from the group consisting of, methyl jasmonate, kopexil, and minoxidil or combination thereof.

6. The personal care composition as claimed in claim 3, wherein the solvent is selected from the group consisting of ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, polyethylene glycol, sorbitol, glycerine, xylitol, and mannitol or combinations thereof.

7. The personal care composition as claimed in claim 1, wherein the personal care composition comprises 10-9 - 1 wt% of astaxanthin; and 10-6 - 1 wt% of folic acid.

8. The personal care composition as claimed in claim 1, wherein the personal care composition comprises 10-9 - 1 wt% of astaxanthin; and 10-6 - 1 wt% of beta-sitosterol.

9. The personal care composition as claimed in claim 1, wherein the personal care composition comprises 10-9 - 1 wt% of astaxanthin; and 10-6 - 1 wt% of L-arginine.

10. The personal care composition as claimed in claim 1, wherein the personal care composition comprises 10-9 - 1 wt% of astaxanthin; 10-6 - 1 wt% of folic acid; and 10-6 - 1 wt% of beta-sitosterol.

11. The personal care composition as claimed in claim 1, wherein the personal care composition comprises 10-9 - 1 wt% of astaxanthin; 10-6 - 1 wt% of L-Arginine and 0.000001-1 wt% 10-6 - 1 wt% of beta-sitosterol.

12. The personal care composition as claimed in claim 1, wherein the personal care composition comprises 10-9 - 1 wt% of astaxanthin; 10-6 - 1 wt% of L-Arginine and 0.000001-1 wt% 10-6 - 1 wt% of folic acid.

13. The personal care composition as claimed in claim 1, wherein the personal care composition comprises 10-9 - 1 wt% of astaxanthin; 10-6 - 1 wt% of folic acid; 10-6 - 1 wt% of beta-sitostero; and 10-6 - 1 wt% of L-Arginine.

14. The personal care composition as claimed in claim 1, wherein the personal care composition is a topical composition formulated as oil, creme, biphasic, gel, solutions, suspensions, dispersions, emulsions, microformulations, nano formulations, nano carriers, lipid based systems, colloidal dispersions, polymer based systems, creams and lotions.